Study on the effectiveness and safety of glibenclamide in the treatment of cerebral edema after aneurysmal subarachnoid hemorrhage

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049908

Enrollment

Unknown

Registered

2021-08-10

Start date

2021-08-11

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aneurysmal subarachnoid hemorrhage

Interventions

Glibenclamide group:Glibenclamide is administered orally at 15mg/ day for 10 days

Control group:No

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Imaging Confirmative Evidence (CT/CTA/DSA) of Aneurysmal Subarachnoid Hemorrhage in patients aged 18-70 years with onset less than 72 hours.

Exclusion criteria

Exclusion criteria: At the time of visit, hypoglycemia (fasting lt;3.9mmol/L) or previous hypoglycemia or previous hypoglycemia caused by taking hypoglycemic drugs, pregnancy, known kidney or liver injury, incomplete independence before bleeding, drug abuse or alcohol dependence, use of warfarin drugs, and other suspected life-threatening diseases.

Design outcomes

Primary

Measure	Time frame
Early brain edema score in subarachnoid hemorrhage;intracranial pressure;Brain Doppler ultrasound PI value;SUR1 protein level;TRPM4 protein level;	—

Secondary

Measure	Time frame
Mortality;Modified Rankin score;Indicators of osmotic drug therapy;Levels of delayed cerebral ischemia and cerebral vasospasm;	—

Countries

China

Contacts

Public ContactXu Yueqiao, Zhang Tongyu

Xuanwu Hospital, Capital Medical University

dr_tongyuzhang@163.com+86 19801172712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026